By The End Of 2028, Biological Age Measurement And AI-driven Target Discovery Will Become A Standard Component Of Preclinical Longevity Programs, Used İn At Least 50% Of Such Programs.

The Rise Of AI And Biological Age Measurement İn Longevity Research

The longevity industry is rapidly growing into a major market as it approaches 2028. According to Source [1], the sector is projected to reach $44.2 billion by 2028 with a compound annual growth rate of 10.8%. Source [2] forecasts a market size of $42.8 billion for 2028 with 8.6% year-over-year growth. This growth signifies increased investment in research and development activities.

The Role Of AI İn Preclinical Research

Source [6] emphasizes that artificial intelligence will increasingly define which aging pathways receive therapeutic investment. By 2030, an estimated 70% of preclinical longevity programs are expected to incorporate generative AI-assisted compound screening, compressing discovery cycles by 40-50% compared to traditional approaches. Extrapolating this trend to the 2028 target year suggests an adoption rate exceeding 50%.

The Importance Of Biological Age Prediction

Biological age prediction is becoming a critical tool for measuring the efficacy of anti-aging interventions. As noted in Source [6], AI-driven target discovery and biological age prediction will determine which aging pathways receive therapeutic investment. This indicates that biological age measurement is progressing toward becoming a standard component in preclinical studies.

Adoption By Institutional Healthcare Systems

Source [5] reveals that institutional healthcare systems are becoming key adopters of longevity solutions in preventive healthcare and personalized medicine. Expanding healthcare infrastructure is improving the capacity to deliver these services. This institutional adoption will serve as a factor accelerating standardization in preclinical research as well.

Impact Of Market Growth On Research

The market data in Source [2] projects steady growth from 2025 to 2028 (from $35.4 billion to $42.8 billion). This financial expansion will enable research organizations to invest more in AI and biological age measurement tools. The 10.8% CAGR forecast in Source [1] further supports this investment momentum.

Inference Toward The 2028 Target

Available evidence suggests that the 70% adoption rate projected for 2030 will reach at least 50% by 2028. The trend in Source [6] demonstrates that AI-assisted methods are rapidly becoming standard in preclinical research. The institutional adoption trend in Source [5] also supports this transformation. Therefore, the use of biological age measurement or AI-driven target discovery in at least half of preclinical longevity programs by the end of 2028 emerges as a high-probability prediction.